Development Reports. Commencing with the beginning of 2003, COMPANY shall furnish, and shall oblige its SUBLICENSEES to furnish to COMPANY for inclusion in its reports to GI, to GI in writing, within 30 (thirty) days after the end of each calendar quarter with COMPANY's standard R&D report, as provided to the investors pursuant to the Amended and Restated Investor's Rights Agreement Series B, on the progress of its efforts during the immediately preceding calendar quarter to develop and commercialize LICENSED PRODUCTS for each indication and sub-indication within the FIELD. The report shall also contain a discussion of intended R&D efforts for the calendar quarter in which the report is submitted.
Appears in 3 contracts
Samples: Co Exclusive License Agreement (Alnylam Pharmaceuticals Inc), Co Exclusive License Agreement (Alnylam Pharmaceuticals Inc), Co Exclusive License Agreement (Alnylam Pharmaceuticals Inc)
Development Reports. Commencing with the beginning of 2003, COMPANY shall furnish, and shall oblige its SUBLICENSEES to furnish to COMPANY for inclusion in its reports to GI[**], to GI [**] in writing, within 30 (thirty) days after the end of each calendar quarter with COMPANY's standard R&D report, as provided to the investors pursuant to the Amended and Restated Investor's Rights Agreement Series B, on the progress of its efforts during the immediately preceding calendar quarter to develop and commercialize LICENSED PRODUCTS for each indication and sub-indication within the FIELD. The report shall also contain a discussion of intended R&D efforts for the calendar quarter in which the report is submitted.
Appears in 2 contracts
Samples: Strategic Collaboration and License Agreement (Alnylam Pharmaceuticals Inc), Strategic Collaboration and License Agreement (Alnylam Pharmaceuticals Inc)
Development Reports. Commencing with the beginning of 2003, COMPANY shall furnish, and shall oblige its SUBLICENSEES to furnish to COMPANY for inclusion in its reports to GI[***], to GI [***] in writing, within 30 (thirty) days after the end of each calendar quarter with COMPANY's ’s standard R&D report, as provided to the investors pursuant to the Amended and Restated Investor's ’s Rights Agreement Series B, on the progress of its efforts during the immediately preceding calendar quarter to develop and commercialize LICENSED PRODUCTS for each indication and sub-indication within the FIELD. The report shall also contain a discussion of intended R&D efforts for the calendar quarter in which the report is submitted.
Appears in 1 contract
Samples: Strategic Collaboration and License Agreement (Isis Pharmaceuticals Inc)
Development Reports. Commencing with the beginning of 2003, COMPANY shall furnish, and shall oblige its SUBLICENSEES to furnish to COMPANY for inclusion in its reports to GI[**], to GI [**] in writing, within 30 (thirty) days after the end of each calendar quarter with COMPANY's ’s standard R&D report, as provided to the investors pursuant to the Amended and Restated Investor's ’s Rights Agreement Series B, on the progress of its efforts during the immediately preceding calendar quarter to develop and commercialize LICENSED PRODUCTS for each indication and sub-indication within the FIELD. The report shall also contain a discussion of intended R&D efforts for the calendar quarter in which the report is submitted.
Appears in 1 contract
Samples: Strategic Collaboration and License Agreement (Alnylam Pharmaceuticals, Inc.)
Development Reports. Commencing with the beginning of 2003, COMPANY shall furnish, and shall oblige its SUBLICENSEES to furnish to COMPANY for inclusion in its reports to GI, to GI in writing, within 30 (thirty) days after the end of each calendar quarter with COMPANY's ’s standard R&D report, as provided to the investors pursuant to the Amended and Restated Investor's Rights Agreement Series B, ...on the progress of its efforts during the immediately preceding calendar quarter to develop and commercialize LICENSED PRODUCTS for each indication and sub-indication within the FIELD. The report shall also contain a discussion of intended R&D efforts for the calendar quarter in which the report is submitted.
Appears in 1 contract
Samples: Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)